Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Podofilox topical solution 0.5?

See the DrugPatentWatch profile for Podofilox

Podofilox 0.5 % topical solution (brand names: Condylox, Podofilox, Steri-Soak, etc.) is a prescription medication used mainly to treat genital and anal warts (condyloma acuminatum) caused by human papillomavirus (HPV).


What it is and how it works

Item Details
Active ingredient Podofilox 0.5 % (a synthetic alkaloid)
Drug class Antimitotic (microtubule‑destabilizing)
Mechanism of action Binds to tubulin in rapidly dividing cells, inhibiting microtubule polymerization, which leads to cell cycle arrest (G2/M) and apoptosis of the wart tissue.
Formulation Clear, slightly viscous liquid (solution).
Prescription status Prescription‑only (in the U.S. and many other countries).

Indications

  • External genital and anal warts (HPV‑related condyloma acuminatum) in adults and adolescents ≥ 12 yrs.
  • Sometimes used for other superficial wart types (e.g., plantar warts) under a clinician’s guidance, though it is not FDA‑approved for those sites.

Typical dosing instructions

For external genital/anal warts
• Apply a thin layer of the solution directly onto the wart(s) and a small margin of surrounding normal skin.
Do not cover the area with a bandage.
• Allow the solution to dry completely (usually 5–10 min).
• Repeat once daily for up to 10 days.
• After 10 days, discontinue the product.
• If warts persist or recur, consult your clinician for alternative therapy.

Caution:

  • Use only on the intended area; avoid contact with mucous membranes, eyes, or broken skin.
  • If accidental exposure occurs, rinse thoroughly with water and seek medical attention if irritation persists.

Contraindications

  • Known hypersensitivity to podofilox or any excipients.
  • Pregnancy and lactation (data are limited; risk‑benefit must be assessed).
  • Use in the setting of active mucosal lesions (unless specifically directed by a provider).

Common adverse effects

System Symptoms Notes
Skin Burning, itching, erythema, scaling, mild edema Usually mild; resolves within a few days after discontinuation.
Oral/ocular Burning, pain if contact occurs Rinse immediately.
Systemic Rare; nausea, headache Very uncommon with topical use.

Important warnings / precautions

  • Avoid contact with mucous membranes: accidental eye exposure can lead to irritation, redness, or blurred vision.
  • Do not use on open sores, cracked skin, or any area of skin compromised by other diseases.
  • Pregnancy: No definitive data; consider alternative treatments.
  • Lactation: Very little is known; discuss with your healthcare provider.

Drug interactions

Podofilox is a topical drug, so systemic interactions are rare. However:

  • Concurrent use of other topical agents (e.g., imiquimod, podophyllotoxin, trichloroacetic acid) may increase irritation or skin damage.
  • Alcohol or other irritants can exacerbate local skin reactions.

Storage

  • Keep the bottle capped and store at 25 °C (77 °F) or below.
  • Do not freeze.
  • Keep out of reach of children.

Patient education key points

  1. Apply only to warts – no more, no less.
  2. Do not cover the treated area – allow it to air dry.
  3. Use for no longer than 10 days in a single course; if warts are still present, stop and seek medical advice.
  4. Rinse thoroughly if it contacts eyes or mucosa.
  5. Report any severe or persistent irritation to your provider.

When to seek medical help

  • Severe or spreading skin reactions.
  • Persistent redness or swelling.
  • Pain or visual changes after eye contact.
  • No improvement after 10 days of treatment or recurrent warts.

Bottom line: Podofilox 0.5 % solution is a safe, effective prescription therapy for genital and anal warts when used as directed. Always follow your clinician’s instructions and report any adverse reactions promptly.



Other Questions About Podofilox :

Podofilox price? Podofilox where to buy? Podofilox alternative? Podofilox condylox price? Podofilox cream? Harga podofilox? Podofilox vs imiquimod?

AI-Drug Label Prescribing Information Alignment Report

48
48%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Several statements align with the provided label excerpt (indication for anogenital warts, twice-daily for 3 days then 4 days off up to 4 cycles, contraindication for hypersensitivity, cutaneous-only/avoid eyes). However, multiple statements are unsupported or conflict with the label excerpt, particularly mechanism of action and several safety/product-use assertions not present in the supplied label text.


Category Scores

Indication
90
Excellent
Dosage
78
Good
Contraindications
85
Good
Warnings
55
Partial
SpecificPopulations
30
Poor
AdverseReactions
65
Partial
Administration
60
Partial

Accurate Statements

Podofilox topical solution is a prescription medication.
Not supported by the provided label excerpts.
Podofilox topical solution is used to treat external genital warts.
Supported indirectly: Condylox Gel 0.5% indicated for topical treatment of anogenital warts (external genital warts and perianal warts).
Podofilox topical solution is available in a 0.5% concentration.
Supported by the provided excerpt referring to Condylox Gel 0.5% and 0.5% podofilox solution.
The cycle of application for three to four consecutive days followed by a four-day treatment-free interval may be repeated up to four times if warts remain.
Supported: Apply twice daily for 3 consecutive days, discontinue for 4 consecutive days; one-week cycle may be repeated until no visible wart tissue or for a maximum of four cycles.
Common side effects of Podofilox topical solution include local irritation at the application site, such as burning, stinging, itching, and redness.
Partially supported: burning and itching listed; stinging and erythema listed as other local adverse events.
Potential side effects of Podofilox topical solution include pain, inflammation, or small sores on the treated area.
Partially supported: inflammation and pain are listed; erosion is listed (a form of tissue damage/lesion) as an adverse reaction category.
Severe skin reactions are rare but possible with Podofilox topical solution.
Supported in direction: severe reactions occurred (table includes severe percentages); severity described as predominantly mild/moderate.

Unsupported Statements

Podofilox topical solution contains podophyllum resin.
The provided label excerpt does not state formulation components for podofilox solution.
Podophyllum resin is a compound derived from the Mayapple plant.
Not stated in the provided label excerpt.
Podophyllum resin is a cytotoxic agent.
Not stated in the provided label excerpt.
Podofilox topical solution works by inhibiting cell growth in the warts.
Not supported by the provided mechanism section. The label states results in necrosis of visible wart tissue and the exact mechanism is unknown.
Podofilox topical solution causes warts to break down and slough off over time.
The provided mechanism states necrosis of visible wart tissue, but the specific phrasing of 'slough off over time' is not directly stated in the excerpt.
Podofilox topical solution is applied directly to the warts.
While application to warts is described for Condylox Gel (applied to the warts with applicator tip or finger), the provided excerpts do not explicitly confirm this statement for 'Podofilox topical solution' as a distinct product form; label excerpt is for Condylox Gel 0.5%.
Podofilox topical solution is typically applied twice a day for three to four consecutive days.
The label excerpt specifies 3 consecutive days, not 'three to four consecutive days'.
After three to four consecutive days, Podofilox topical solution use includes a four-day treatment-free interval.
Label specifies 3 consecutive days followed by 4 consecutive days off; 'three to four consecutive days' is not supported.
The cycle of application for three to four consecutive days followed by a four-day treatment-free interval may be repeated up to four times if warts remain.
The repetition concept is supported, but the 'three to four consecutive days' part is not.
Podofilox topical solution should not be used by individuals with weakened immune systems.
Not stated in provided label excerpt sections.
Podofilox topical solution should not be used by pregnant or breastfeeding women.
Label excerpt does not contraindicate pregnancy or nursing; it provides pregnancy caution (use only if benefit justifies risk) and nursing decision-making.
Podofilox topical solution should not be used in individuals with open sores or broken skin in the genital area.
Not stated in provided label excerpt.
Podofilox topical solution is not suitable for everyone.
This is a vague generalization; not directly supported by provided label excerpts.
Podofilox topical solution is a prescription medication.
Not stated in provided label excerpt.

Contradictions

Low

AI Statement
Podofilox topical solution works by inhibiting cell growth in the warts.

Label Reference
Mechanism of Action section states: 'Treatment ... results in necrosis of visible wart tissue. The exact mechanism of action is unknown.'

Low

AI Statement
Podofilox topical solution should not be used by pregnant or breastfeeding women.

Label Reference
Pregnancy section: 'Condylox Gel 0.5% should be used during pregnancy only if the potential benefit justifies the potential risk.' Nursing Mothers: decision to discontinue nursing or drug based on importance.

Low

AI Statement
Podofilox topical solution is typically applied twice a day for three to four consecutive days.

Label Reference
DOSAGE AND ADMINISTRATION: 'Apply twice daily for 3 consecutive days, then discontinue for 4 consecutive days.'


Important Omissions

Important administration limits from the label excerpt are not included in the AI statements: limit treatment to 10 cm^2 or less and no more than 0.5 g of gel per day; minimize application on surrounding normal tissue; allow gel to dry before returning opposing skin surfaces; wash hands before and after each application; discontinue if incomplete response after four cycles.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
The response includes several statements not supported by the provided label excerpt (e.g., pregnancy/breastfeeding as 'should not be used') and some dosing imprecision (3 to 4 days instead of 3). It also omits key administration limits (area and maximum daily amount) and other label-specific safety instructions.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Partially Aligned

Primary Issue
Multiple safety-related statements (pregnancy/nursing) contradict the provided label excerpt and several dosing/administration details are inaccurate or omitted (e.g., 'three to four consecutive days', lack of area/maximum daily dose limits).

Suggested Improvement
Align dosing to exactly '3 consecutive days then 4 days off' and explicitly include label administration limits (≤10 cm^2 and ≤0.5 g/day), and replace contraindictory pregnancy/nursing statements with the label’s risk/benefit language. Remove unsupported formulation and mechanism claims not present in the provided label excerpt.

Drug Brand Mention Assessment

Branding Score
58
Visibility
65
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

prescription medication used to treat external genital warts


Core Claims
  • Podofilox topical solution is a prescription medication used to treat external genital warts
  • It is available in a 0.5% concentration
  • It works by inhibiting cell growth in the warts
  • It is applied directly to the warts to cause them to break down and slough off over time
  • Common side effects include local irritation at the application site
Differentiators
  • Contains podophyllum resin derived from the Mayapple plant
  • Cytotoxic agent that inhibits cell growth in the warts
  • Applied directly to the warts with a twice-daily, multi-day cycle followed by a treatment-free interval

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Imiquimod 52%
50 #5 No
Sinecatechins 48%
50 #6 No